Literature DB >> 15501552

Dendritic cells in vaccination therapies of human malignant disease.

Volker L Reichardt1, Peter Brossart, Lothar Kanz.   

Abstract

Dendritic cells (DC) are the most efficient antigen presenting cells in various in vitro systems and DC are now introduced to early clinical use. Tumor antigen loaded DC might potentially add therapeutic benefit with dendritic cell based vaccination. This review will focus on dendritic cell biology relevant to investigators who work in transitional research programs and will discuss the rationale of DC source, antigen loading and route of vaccination. An overview of published and on-going clinical trials in human malignant diseases will be provided forming the basis for a discussion of perspectives of dendritic cell vaccination in various human malignancies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15501552     DOI: 10.1016/j.blre.2003.12.001

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  12 in total

Review 1.  Enhancement of dendritic cells as vaccines for cancer.

Authors:  Meghan E Turnis; Cliona M Rooney
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

2.  Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Authors:  Natalia Lapteva; Melissa Aldrich; David Weksberg; Lisa Rollins; Tatiana Goltsova; Si-Yi Chen; Xue F Huang
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

3.  Maturation and upregulation of functions of murine dendritic cells (DCs) under the influence of purified aromatic-turmerone (AR).

Authors:  Tan Yonggang; Meng Yiming; Zhang Heying; Sun Cheng; Wang Qiushi; Yang Xianghong; Zheng Wei; Zhou Huawei; Fengping Shan
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 4.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

5.  Maturation induction of human peripheral blood mononuclear cell-derived dendritic cells.

Authors:  Dong-Yin Li; Chuan Gu; Jun Min; Zhong-Hua Chu; Qing-Jia Ou
Journal:  Exp Ther Med       Date:  2012-05-02       Impact factor: 2.447

Review 6.  In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.

Authors:  Linda Hammerich; Adam Binder; Joshua D Brody
Journal:  Mol Oncol       Date:  2015-11-10       Impact factor: 6.603

Review 7.  Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.

Authors:  R Oostvogels; H M Lokhorst; T Mutis
Journal:  Bone Marrow Transplant       Date:  2015-10-26       Impact factor: 5.483

8.  Rapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading.

Authors:  Maria Salskov-Iversen; Carole L Berger; Richard L Edelson
Journal:  J Immune Based Ther Vaccines       Date:  2005-07-19

9.  Improved generation of anti-tumor immunity by antigen dose limitation.

Authors:  Joshua D Shofner; Juan G Vasquez; Carole L Berger; Richard L Edelson
Journal:  J Immune Based Ther Vaccines       Date:  2007-02-09

Review 10.  Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.

Authors:  Ilse Van Brussel; Zwi N Berneman; Nathalie Cools
Journal:  Mediators Inflamm       Date:  2012-07-18       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.